These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22939417)

  • 1. The carbapenem-resistant Enterobacteriaceae score: a bedside score to rule out infection with carbapenem-resistant Enterobacteriaceae among hospitalized patients.
    Martin ET; Tansek R; Collins V; Hayakawa K; Abreu-Lanfranco O; Chopra T; Lephart PR; Pogue JM; Kaye KS; Marchaim D
    Am J Infect Control; 2013 Feb; 41(2):180-2. PubMed ID: 22939417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised.
    Deshpande P; Rodrigues C; Shetty A; Kapadia F; Hedge A; Soman R
    J Assoc Physicians India; 2010 Mar; 58():147-9. PubMed ID: 20848811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
    Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simple bedside score to optimize the time and the decision to initiate appropriate therapy for carbapenem-resistant Enterobacteriaceae.
    Leibman V; Martin ET; Tal-Jasper R; Grin L; Hayakawa K; Shefler C; Azouri T; Kaplansky T; Maskit M; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
    Ann Clin Microbiol Antimicrob; 2015 Jun; 14():31. PubMed ID: 26041137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.
    Palacios-Baena ZR; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina Gil-Bermejo J; Hernández A; Venditti M; Prim N; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Paño-Pardo JR; Torre-Cisneros J; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual Á; Rodríguez-Baño J;
    Clin Infect Dis; 2017 Oct; 65(10):1615-1623. PubMed ID: 29020250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.
    Khoo AL; Zhao YJ; Teng M; Ying D; Jin J; Chee YL; Poon LM; Lim SE; Koh LP; Chng WJ; Lim BP; Hsu LY; Chai LYA
    Int J Antimicrob Agents; 2018 Sep; 52(3):350-357. PubMed ID: 29751120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbapenem-resistant enterobacteriaceae: an emerging problem in children.
    Logan LK
    Clin Infect Dis; 2012 Sep; 55(6):852-9. PubMed ID: 22700827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
    Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J;
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
    Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
    Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of carbapenem-resistant Enterobacteriaceae isolates in the Moroccan community.
    Barguigua A; El Otmani F; Talmi M; Zerouali K; Timinouni M
    Diagn Microbiol Infect Dis; 2012 Jul; 73(3):290-1. PubMed ID: 22521054
    [No Abstract]   [Full Text] [Related]  

  • 12. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
    Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
    J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae.
    Martirosov DM; Lodise TP
    Diagn Microbiol Infect Dis; 2016 Jun; 85(2):266-75. PubMed ID: 27033631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management.
    Temkin E; Adler A; Lerner A; Carmeli Y
    Ann N Y Acad Sci; 2014 Sep; 1323():22-42. PubMed ID: 25195939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of prior colonization and antibiotic use for third-generation cephalosporin-resistant enterobacteriaceae bacteremia in patients with sepsis.
    Rottier WC; Bamberg YR; Dorigo-Zetsma JW; van der Linden PD; Ammerlaan HS; Bonten MJ
    Clin Infect Dis; 2015 Jun; 60(11):1622-30. PubMed ID: 25694654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy.
    Viale P; Tumietto F; Giannella M; Bartoletti M; Tedeschi S; Ambretti S; Cristini F; Gibertoni C; Venturi S; Cavalli M; De Palma A; Puggioli MC; Mosci D; Callea E; Masina R; Moro ML; Lewis RE
    Clin Microbiol Infect; 2015 Mar; 21(3):242-7. PubMed ID: 25658534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital.
    Souli M; Kontopidou FV; Papadomichelakis E; Galani I; Armaganidis A; Giamarellou H
    Clin Infect Dis; 2008 Mar; 46(6):847-54. PubMed ID: 18269335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
    Mendes RE; Rhomberg PR; Bell JM; Turnidge JD; Sader HS
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demographic and infection characteristics of patients with carbapenem-resistant Enterobacteriaceae in a community hospital: Development of a bedside clinical score for risk assessment.
    Miller BM; Johnson SW
    Am J Infect Control; 2016 Feb; 44(2):134-7. PubMed ID: 26492818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing prevalence of carbapenem-resistant Enterobacteriaceae and strategies to avert a looming crisis.
    Watkins RR; Bonomo RA
    Expert Rev Anti Infect Ther; 2013 Jun; 11(6):543-5. PubMed ID: 23750724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.